Show simple item record

dc.contributor.authorSánchez-Paulete, Alfonso R
dc.contributor.authorTeijeira, Álvaro
dc.contributor.authorQuetglas, José I
dc.contributor.authorRodríguez-Ruiz, María E
dc.contributor.authorSánchez-Arráez, Álvaro
dc.contributor.authorLabiano, Sara
dc.contributor.authorEtxeberria, Iñaki
dc.contributor.authorAzpilikueta, Arantza
dc.contributor.authorBolaños, Elixabet
dc.contributor.authorBallesteros-Briones, María Cristina
dc.contributor.authorCasares, Noelia
dc.contributor.authorQuezada, Sergio A
dc.contributor.authorBerraondo, Pedro
dc.contributor.authorSancho, David 
dc.contributor.authorSmerdou, Cristian
dc.contributor.authorMelero, Ignacio
dc.identifier.citationCancer Res. 2018; 78(23):6643-54es_ES
dc.description.abstract: Multiple lines of evidence indicate a critical role of antigen cross-presentation by conventional BATF3-dependent type 1 classical dendritic cells (cDC1) in CD8-mediated antitumor immunity. Flt3L and XCL1, respectively, constitute a key growth/differentiation factor and a potent and specific chemoattractant for cDC1. To exploit their antitumor functions in local immunotherapy, we prepared Semliki Forest Virus (SFV)-based vectors encoding XCL1 and soluble Flt3L (sFlt3L). These vectors readily conferred transgene expression to the tumor cells in culture and when engrafted as subcutaneous mouse tumor models. In syngeneic mice, intratumoral injection of SFV-XCL1-sFlt3L (SFV-XF) delayed progression of MC38- and B16-derived tumors. Therapeutic activity was observed and exerted additive effects in combination with anti-PD-1, anti-CD137, or CTLA-4 immunostimulatory mAbs. Therapeutic effects were abolished by CD8β T-cell depletion and were enhanced by CD4 T-cell depletion, but not by T regulatory cell predepletion with anti-CD25 mAb. Antitumor effects were also abolished in BATF3- and IFNAR-deficient mice. In B16-OVA tumors, SFV-XF increased the number of infiltrating CD8 T cells, including those recognizing OVA. Consistently, following the intratumoral SFV-XF treatment courses, we observed increased BATF3-dependent cDC1 among B16-OVA tumor-infiltrating leukocytes. Such an intratumoral increase was not seen in MC38-derived tumors, but both resident and migratory cDC1 were boosted in SFV-XF-treated MC38 tumor-draining lymph nodes. In conclusion, viral gene transfer of sFlt3L and XCL1 is feasible, safe, and biologically active in mice, exerting antitumor effects that can be potentiated by CD4 T-cell depletion. SIGNIFICANCE: These findings demonstrate that transgenic expression of sFLT3L and XCL1 in tumor cells mediates cross-priming of, and elicits potent antitumor activity from, CD8 T lymphocytes, particularly in combination with CD4 T-cell depletion.es_ES
dc.description.sponsorshipWe are in debt to Eneko Elizalde for excellent animal facility care. Critical reading and suggestions by Drs. Sandra Hervas, Carmen Ochoa, Jose L. Perez-Gracia, Ana Rouzaut, and Juan Jose Lasarte are also much appreciated. This work was supported by grants MINECO SAF 2014-52361-R and SAF 2017-83267-C2-1R and Cancer Research Institute (CRI) CLIP Grant 2017 and the Horizon 2020 Programme from the European Comission (PROCROP project, ref. #635122) to I. Melero; FIS (PI14/01442 and PI17/01859 (to C. Smerdou); and Fundacion Echebano fellowship (to M.C. Ballesteros-Briones).es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshCD4-Positive T-Lymphocytes es_ES
dc.subject.meshCD8-Positive T-Lymphocytes es_ES
dc.subject.meshChemokines, C es_ES
dc.subject.meshCross-Priming es_ES
dc.subject.meshDendritic Cells es_ES
dc.subject.meshGenetic Vectors es_ES
dc.subject.meshImmunotherapy es_ES
dc.subject.meshMembrane Proteins es_ES
dc.subject.meshMice es_ES
dc.subject.meshSemliki forest virus es_ES
dc.subject.meshT-Lymphocytes es_ES
dc.subject.meshTumor Microenvironment es_ES
dc.titleIntratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priminges_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderCancer Resarch Institutees_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.identifier.journalCancer researches_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Inmunobiologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional